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Introduction
Predicting the future is big business in health care and medical
research. Prognosis research focuses on the risk of future outcomes
among individuals with a given disease or health condition and
how this can be used to make care more effective [1]. It spans a
wide spectrum of activity using study designs from both sides of the
observational-experimental divide ([1–4]), ranging from the
discovery of novel markers of prognosis [5], via multivariable risk
prediction modelling [6], to randomised clinical trials (RCTs) of
the impact of introducing prognosis tools into clinical practice [7].
The information on which it can draw is expanding rapidly, as
databases linking health care data to genetic, biological, psycho-
logical, and social measures become widely available.
Recent examples of the significance of prognosis research
include the relevance of international contrasts in breast cancer
mortality for national policies of cancer registration and service
organisation [8]; disparities between UK and Sweden in short-
term survival following acute myocardial infarction and large
differences in the uptake of primary percutaneous coronary
intervention and beta-blockers [9]; the less favourable cost-
effectiveness of treatment when evaluated using data on prognosis
and patterns of use in ‘‘real-world’’ clinical practice as opposed to
narrow trials data [10]; and the recent call to better understand the
natural history of small pulmonary emboli detected by computed
tomography pulmonary angiography [11], which reflects wider
concern over the prognostic relevance of incidental findings from
new diagnostic technologies.
The consequences of poor prognosis research for policy and
practice are substantial too. The high-profile retraction of
publications reporting better prediction of cancer outcomes by
novel gene expression profiling [12] came only after erroneous
findings had been extensively cited in the medical literature and
used to justify initiating three clinical trials. A lack of consistently
strong data management, lack of independent confirmation of the
initial discovery, failure to lock down the specific test methods, and
inadequate validation of the prognostic test prior to commencing
clinical trials, all contributed to this failure [13]. Whistle-blowers
responsible for identifying the failure advocated sharing of datasets
and details of analysis to enable rapid replication [14]. Such cases
may be exceptional, but the quality and rigor of much prognosis
research has been more widely questioned [15]. Systematic
reviews in prognostic factor research have failed to reach robust
The Guidelines and Guidance section contains advice on conducting and
reporting medical research.
Citation: Peat G, Riley RD, Croft P, Morley KI, Kyzas PA, et al. (2014) Improving the
Transparency of Prognosis Research: The Role of Reporting, Data Sharing,
Registration, and Protocols. PLoS Med 11(7): e1001671. doi:10.1371/journal.pmed.
1001671
Published July 8, 2014
Copyright:  2014 Peat et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This paper was developed after the participation of all authors in a
workshop on the topic, organised by the MRC PROGnosis RESearch Strategy
(PROGRESS) Partnership (www.progress-partnership.org), which is supported by a
Medical Research Council Partnership Grant (G0902393) involving University
College London (HH, Aroon Hingorani, KIM), Oxford University (DGA), Birmingham
University (RDR), London School of Hygiene & Tropical Medicine (Ian Roberts, PP),
Keele University (PC, Danie ¨lle van der Windt), and Queen Mary University London
(Adam D Timmis). DGA is supported by a programme grant from Cancer Research
UK (C5529). HH is supported by grants from the UK National Institute for Health
Research (RP-PG-0407-10314; http://www.nihr.ac.uk/), and the Wellcome Trust
(086091/Z/08/Z; http://www.wellcome.ac.uk/) and by awards establishing the Farr
Institute of Health Informatics Research at UCLP Partners from the MRC, in
partnership with Arthritis Research UK, the British Heart Foundation, Cancer
Research UK, the Economic and Social Research Council, the Engineering and
Physical Sciences Research Council, the National Institute of Health Research, the
National Institute for Social Care and Health Research (Welsh Assembly
Government), the Chief Scientist Office (Scottish Government Health Directorates)
and the Wellcome Trust (MR/K006584/1). EWS was partly funded by the NIH (NS-
042691). KGMM is supported by The Netherlands Organization for Scientific
Research (ZON-MW 918.10.615 and 91208004). GP, PC, and Danielle van der Windt
are supported by the Arthritis Research UK Centre of Excellence in Primary Care.
PC is a UK NIHR Senior Investigator. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
Abbreviations: IPD, individual patient data; RCT, randomised clinical trial.
* Email: g.m.peat@keele.ac.uk
These authors contributed equally and are joint first authors.
Provenance: Not commissioned; externally peer reviewed.
"
Membership of the PROGRESS Group is listed in the Acknowledgments.
PLOS Medicine | www.plosmedicine.org 1 July 2014 | Volume 11 | Issue 7 | e1001671
`
"
`conclusions, citing publication bias, selective reporting of results,
inadequate measurement of confounding, bias in study design, and
small sample sizes within primary studies [16–18]. Holmes and
colleagues [19], in their systematic review and meta-analysis of
CYP2C19 genotype as a predictor of differential response to
clopidogrel, found many ‘‘treatment only’’ studies ill-suited to
evaluating differential treatment response, and evidence of
publication bias in small studies. The conclusion of the review
challenged US Food and Drug Administration recommendations
for genotyping to be considered before prescribing clopidogrel.
Prognosis research using cohort studies is no different to RCTs
in requiring rigorously peer-reviewed protocols on which to base
funding and ethical approval. Yet the need for transparency
measures in prognosis research, including registration and pre-
published protocols, similar to those expected and encouraged for
RCTs by funders and journal editors and bodies such as the World
Health Organization, is not widely recognised or accepted, despite
recent calls for reform of journal and funders’ policies towards
transparency in observational research [20,21].
Our ambition is to highlight why a concern for the transparency
of prognosis research is an urgent and important priority for the
public, patients, and medical and health care and research
communities. We base this ambition on the unique perspective of
prognosis research spanning observational studies and clinical
trials, its rapidly expanding importance for clinical decision-
making and health policy, and the demonstrable consequences of
poor quality studies. In this paper we consider the arguments that
have been made for and against measures to improve transpar-
ency, and emphasise practical measures to achieve better
transparency for prognosis studies. Our appeal is principally to
the research community, although we draw attention to the
broader debate and changing policy environment. We consider
the case for action on four issues: complete and accurate peer-
reviewed reporting of study findings, facilitation of data sharing,
study registration, and publicly accessible study protocols. We
make recommendations for improving the transparency of
prognosis research.
Complete and Accurate Reporting
Transparent and complete study reporting is important because
decision making in clinical practice and policy relies on bias-free
evidence, and study generalizability and usefulness for meta-
analysis and decision modelling rely on completeness and detail
[22].
Reporting deficiencies in published prognosis studies are
common [23–25], with omission of rudimentary results and
methods such as the number of patients and events, or the number
of prognostic candidate factors examined. Simon [26] comments
that prognosis literature ‘‘is probably cluttered with ‘false-positive’
studies that would not have been submitted or published if the
results had come out differently,’’ although this view has been
challenged [27]. Within-study selectivity is probably worse than for
trials because reports focus on prognostic factors, endpoints,
threshold levels, and subgroups that produce ‘‘favourable’’ results.
For observational studies and some types of prognosis studies,
reporting guidelines exist, but are not widely used. Relevant for
studies that investigate whether specific factors influence patient
outcome (‘‘prognostic factor studies’’) are published guidelines for
tumour marker research (REporting recommendations for tumor
MARKer prognostic studies [REMARK] [28]), which cover all
components of the study process from hypotheses to results and
limitations. The importance of clear reporting for particular study
designs is emphasized in reporting guidelines for studies designed
to develop models that predict an individual’s likelihood of a
particular outcome (‘‘prognostic model studies’’) (TRIPOD:
http://blogs.bmj.com/bmj/2011/08/03/gary-collins-opening-up-
multivariable-prediction-models/) and for studies that use elec-
tronic health records (RECORD [29]).
Data Sharing
Data sharing makes data collected for one purpose accessible to
other investigators, including data curation activities such as
documentation of meta-data (data about data), harmonisation
procedures, and tools to support the accessibility of datasets. All
these activities need to be conducted within a strong governance
framework. Important examples include large scale biobank
cohorts [30] and e-health record linkages [31].
Patient concern about regulation of use of their data for
research co-exists with public interest in ensuring maximal benefits
for the public from such data. However, realising this goal on a
large scale requires navigation through consent and confidential-
ity; standards and frameworks for data formatting; planning and
management of original data; funding and incentives for data
archiving and intellectual property; and communication between
custodians and secondary users of data [32]. The exact
governance, consent, and access arrangements that are in place
will determine the nature and extent of data sharing, and funders’
policies in this area continue to evolve (http://www.wellcome.ac.
uk/About-us/Policy/Spotlight-issues/Data-sharing/EAGDA/index.
htm). Current options include the negotiation of secure, remote
access to anonymised data (e.g., access to Swedish registry data by
Chung et al. [9]), the release of copies of whole or selected parts of
anonymised datasets subject to data sharing agreements (e.g.,
Osteoarthritis Initiative, http://oai.epi-ucsf.org/datarelease/), or
the preference for researchers to come and analyse the data at the
host centre (as per Danish National Birth Cohort (http://www.
ssi.dk/English/RandD/Research%20areas/Epidemiology/DNBC/
For%20researchers/Conditions%20for%20access%20to%20data.
aspx)).
Data sharing for prognosis research is uncommon and most
meta-analyses do not use individual patient data (IPD). Several
reports have considered pros and cons [32,33]; Altman and
colleagues [34] conclude that obtaining IPD was ‘‘long,
expensive, and … laborious.’’ However, IPD meta-analyses of
Summary Points
N Prognosis research is concerned with predicting out-
comes to make health care more effective. It has a crucial
role to play in clinical and policy decision-making.
N The quality of much prognosis research is poor,
evidenced by incomplete reporting, poor data sharing,
incomplete registrations, and absent study protocols.
N Initiatives to improve transparency in trials include
reporting guidelines, data pooling, registers, and journal
requirements for protocols. Prognosis research could be
transformed by similar initiatives.
N Routine registration of all prognostic studies, linked to
an accessible study protocol using agreed reporting
guidelines, would improve transparency and promote
data sharing.
N Concern about applying transparency methods to
observational research could be resolved by flexibility
to update date-stamped protocols during prognosis
studies.
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48 published IPD meta-analyses of prognostic factors [36].
In traumatic brain injury, researchers initiated IMPACT
(International Mission for Prognosis and Analysis of Clinical
Trials) and meta-analysed IPD from 11 studies including 9,205
patients [37].
Registration and data sharing in trials has enabled adequately
powered IPD meta-analyses to examine predictors of differential
treatment response and development of prognostic models using
IPD from multiple trials or prognosis studies. Such initiatives show
that data sharing and international collaboration is possible and
productive in prognosis research, and should encourage others as
the volume of information available for analysis on a large-scale
from health care and genetic databases continues its rapid
expansion.
Funders of prognosis research should require data sharing with
appropriate governance. This requirement is increasingly occur-
ring as applicants are routinely asked to specify how new data is
to be shared and made accessible (e.g., www.mrc.ac.uk/
Fundingopportunities/Grants/Researchgrant/index.html).
Vandenbroucke [27] has raised concerns about the double-
edged nature of data sharing (‘‘re-analysis is a superb tactic to
delay regulation’’ of treatments or exposures found to be harmful,
for example). Against this concern is trials literature that long ago
demonstrated that timely meta-analysis would have produced
earlier results [38] and IPD would logically extend that capacity.
Integrated data from prognosis studies, facilitated by standardisa-
tion of methods and measures, could deliver timely, practical
results to support clinical decisions. One-off prognosis studies will
rarely drive clinical practice.
Study Registration
Study registers hold an internationally agreed minimum amount
of information about research studies in a publicly available
database. Trials registration was proposed to meet ethical
obligations and reduce bias through better design, encouragement
to publish, and full outcome reporting [39]. Several registries meet
the International Committee of Medical Journal Editors (ICMJE)
requirements, and advance registration is a condition for trial
publication in many but not most leading journals [40,41].
However some claimed benefits have been challenged [42].
Two decades ago, Dickersin proposed that ‘‘registration of
clinical trials, and perhaps other types of studies, is …(where)
…scientific community should move’’ [43]. Observational studies
now constitute a small but increasing minority of registered studies
on ClinicalTrials.gov (15% in 2006 to 21% in 2012); fewer than
1% are indexed using the terms ‘‘prognosis’’ or ‘‘prognostic.’’
Recent papers have considered the general case for registration of
observational studies [44]. Others have questioned uncritical
application of arguments and policies derived from clinical trials to
observational studies [45].
Reducing Publication and Reporting Bias
Bias due to non-publication and within-study selective reporting
exists in prognosis research. Kyzas and colleagues [23] found
fewer than 2% of 1,915 articles on cancer prognostic factors
contained no positive findings at all. Registration aligns with the
need, recognised by proponents and opponents of registration
alike, to abandon the culture of uncontrolled questing in datasets
and reliance on significance testing to find ‘‘positive’’ study results.
Given evidence about selective non-publication and reporting of
prognosis studies, and unnecessary duplication of effort, study
registration should help address these issues.
Some critics suggest many unpublished studies may simply be
‘‘fatally flawed… [or] of little consequence’’ [46], with registration
simply uncovering more small, single-centre studies. They
highlight the unpredictable effects of including unpublished trials
in meta-analyses. The counterargument is that advance registra-
tion permits evaluation of these effects, even though it may not in
itself prevent bias.
Evaluation Versus Discovery, and the ‘‘Universe of All
Ideas’’
Vandenbroucke [47] has distinguished ‘‘evaluation’’ from
‘‘discovery.’’ Evaluation provides a single chance, optimally in a
randomised trial, to test an intervention that might affect many
lives, and needs to be highly regulated. Discovery pursues novel
analyses as ideas develop during a particular study, which
excessive regulation would hamper.
Prognosis research, however, blurs this distinction—assessment
of outcomes is related to a wide universe of potential prognostic
factors, and needs a simple framework for describing research
planned and in progress. The need to account for all possible
analyses is underlined by the rapid expansion of studies using large
e-health databases from clinical practice.
Having a comprehensive register of ideas allows assessment of
the universe of studies from which published results appear. Lash
[42] and others argue that registration of whole databases, rather
than individual studies, is the preferable route. But Thomas and
Peterson [48] instead concluded that the potential gains from
registering analysis plans (guarding against data dredging,
reducing duplication) outweigh concerns (analyses dismissed if
not pre-specified). They argue that analysis plans can be flexible
enough to incorporate subsequent findings, and be revisited if
there is a compelling reason.
Evidence for the Benefits of Registration in Randomised
Clinical Trials
Evidence about the effects of trial registration is limited.
Reporting per guidelines is more complete for registered RCTs,
but fewer than half are adequately registered. Registration does
not prevent selective reporting altogether, but does help its
identification. Van Enst and colleagues [49] found that, out of 210
Cochrane reviews of trials, only 80 had searched registries and 28
used them to identify additional trials.
This finding suggests trial registration is evolving and incom-
plete rather than misguided, and contradicts concerns that
researchers might register every idea imaginable to claim territory
and deter competition [45].
Costs of Registration to Researchers
Costs and time needed to register are potential disadvantages
for less well-resourced researchers, hindering rapid production of
evidence or other ‘‘quirky, brilliant work that is not enterprise-
driven’’ [45]. However fees are either non-existent (e.g., Clinical-
Trials.gov) or reasonable (UK£210 plus VAT for International
Standard Randomised Controlled Trial Number [ISRCTN]), and
the level of detail needed to meet the main purpose of informing
the scientific community of a study’s existence does not impose a
great burden on researchers.
Content of Registration
Williams and colleagues [44] highlight how observational
studies, including prognosis studies, can be added to an existing
trial register (ClinicalTrials.gov), although it is acknowledged that
these registries are likely to provide a better fit for new studies with
PLOS Medicine | www.plosmedicine.org 3 July 2014 | Volume 11 | Issue 7 | e1001671prospective data collection [44] and that they are more
cumbersome and challenging for prognosis studies based on re-
analysis of existing datasets. Nevertheless, whole databases and
patient registries can also be included [50], together with their
primary outcome measurements and links to further information
of particular importance for prognosis research, e.g., baseline
variables. Table 1 outlines elements of a prognosis study or dataset
that may be important to consider for registration, protocols,
reporting, and data sharing. The WHO 20-item Trial Data Set is
largely contained in these.
How far to require pre-specification of all analyses of prognosis
data? One advantage of a register (as compared with journal
publication of a protocol) is that it can be updated to incorporate
new information or planned objectives, and the date of updating
archived. New registers designed for prognosis research, starting
with studies planning prospective data collection, may eventually
provide the best approach, although the merits of cross-disease,
cross-research-question registries need to be considered.
Timing of Registration
Given that registers should provide a view of current prognosis
research activity, registration should occur early—prior to data
acquisition for planned cohort studies, and prior to sampling or
analysis for prognosis studies of pre-existing cohorts or datasets.
Figure 1 illustrates optimal points. Sørenson and Rothman [45]
point out that this timing does not preclude bias in the selection of
pre-specified analyses. However, it does allow the pool of intended
analyses from which publications are drawn, and the selectivity of
the pre-specified questions, to be examined.
Publicly Accessible Study Protocol
The Case for Protocols
Protocols describe the rationale, objectives, design, methodol-
ogy, statistical considerations, and organisation of a study and they
present a research plan made before the conduct of the study.
Compared to study registers, protocols contain more detail,
particularly about study design and analysis plans. There is a
strong link between what appears in a protocol and what is
reported in research publications, which may mirror reporting
guidelines (e.g., REMARK [28]) or guidelines for data collection
and curation (e.g., MIAME [51] for gene expression studies).
Most reports from prognosis studies do not refer to a protocol.
Prognosis studies are often piecemeal and opportunistic with no
peer reviewed funding or protocols. Most do not explicitly build on
previous findings, are often too small to answer the research
question, and typically do not provide sample size calculations
[24,25]. Yet funders, ethical committees, and dataset curators
require rigorous peer-reviewed protocols before approving prog-
nosis studies. In this way they ensure that researchers make their
work amenable to comment and have to critically consider key
elements in design prior to data acquisition or analysis, and this
helps drive originality and quality in prognosis research. The
expectation therefore is that all prognosis studies should have a
Table 1. Elements to consider including in registration, protocols, reporting, and data sharing
a.
Stage Elements
Governance Title
b; version
b; date
b; principal investigator(s)
b; contacts
b; sponsors
b; institutional review board/ethics committee approval
b; funding source
b
Rationale Translational gap or other scientific uncertainty being addressed
Objective(s) Type of prognosis research, e.g., according to PROGRESS framework [1]:
(i) the course of health related conditions in the context of the nature and quality of current care (fundamental prognosis research);
(ii) specific factors (such as biomarkers) that are associated with prognosis (prognostic factor research);
(iii) the development, validation, and impact of statistical models that predict individual risk of a future outcome (prognostic model research);
(iv) the use of prognostic information to help tailor treatment decisions to an individual or group of individuals with similar characteristics
(stratified medicine research)
Study design Design type (e.g., randomised trial, prospective cohort, utilisation of existing database, systematic review)
Target population, eligibility criteria
b, startpoint, clinical setting
b
Disease/health condition phenotyping
b;
Treatments used;
Factors of interest (e.g., definitions, timing, and methods of measurement);
Sample size (e.g., rationale, expected number of events)
b;
Primary and secondary endpoints (e.g., definitions, timing, and methods of measurement)
b.
Cross reference to study registration, protocol, report(s), data sharing policy
Statistical methods Statistical analysis techniques (e.g., logistic, survival regression)
Strategy for including multiple variables (e.g., model selection choice);
Dealing with missing data (e.g., complete case analysis versus multiple imputation);
Handling of continuous variables (e.g., variable transformation, modelling non-linear trends, choice of threshold level if any);
Choice of subgroup analyses;
Measures to assess model performance (e.g., internal validation; external validation criterion)
Results Document how results will be presented, including:
Descriptive results (e.g., number of patients and events);
Kaplan-Meier curves;
Univariable and multivariable results for each factor and outcome;
Effect estimates (e.g., odds ratios, hazard ratios) and confidence intervals;
Prognostic model parameter estimates
Summary statistics and graphs for model performance (e.g., calibration and discrimination);
Estimate (with confidence interval) of interaction between factor and treatment effect
aStages mirror the structure of research publications; registration tends to have fewer elements.
bOverlap with WHO Trial Registration Dataset v1.2.1. and ClinicalTrials.gov.
doi:10.1371/journal.pmed.1001671.t001
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sampling and analysis of established datasets, timings that align with
our recommendations for registration. Electronic records of study
protocols, including date stamping, will enable documentation of
the conception of a planned analysis (e.g., pre-, ad-, or post-hoc).
However, a prognosis research protocol cannot be a rigid
blueprint; it is neither possible nor desirable to pre-specify all
analyses. A protocol may state that the goal is exploration, or that
modification or additional analyses may be needed in the light of
new findings. Even highly exploratory or data-driven analyses to
discover new prognostic factors can have a protocol, albeit in
broad terms. A possible exception would be analyses of already-
collected data aimed at immediate replication of important or
controversial discoveries where ideally the protocol from the work
that is being replicated would be available. Exploration of pre-
existing and readily available data is an accepted, valuable part of
epidemiologic research practice. This activity can, in our view, co-
exist with a move towards greater transparency for all prognosis
studies; if a study is exploratory this can be stated.
Benefits of an Accessible Protocol
Evidence is accruing for the benefits of making a pre-specified
protocol publicly available. It allows scientific peers in principle to
replicate the study; easier identification of, and access to, full study
details; and more opportunities for collaboration including
systematic reviews and IPD meta-analyses. The existence of a
publicly available protocol enhances the credibility of the research,
permits authors to cross-reference detail to the protocol, and
provides a basis for defending ‘‘negative’’ or statistically non-
significant results to editors and reviewers. Experience with trials is
that an accessible protocol, together with registration, facilitates
systematic evaluation of selective non-publication and reporting
[39]. An accessible protocol can be compared against final reports
to identify potential reporting bias, and allows the researcher to
defend choice of outcomes.
Making Prognosis Research Study Protocols Accessible
Stand-alone publication of protocols in journals is one option
and creative new models of publishing, including in-principle
acceptance of papers arising from pre-registered and reviewed
protocols [52], may provide further encouragement to researchers.
However, the number of study protocols available by this route is
currently limited, as is the scope for updating protocols.
The other option is that protocols (whether or not they are
journal publications) are made accessible by linkage to registration
(e.g., using the ‘‘Detailed Description’’ field of ClinicalTrials.gov
or as an attachment under ‘‘More Information’’). Dated protocol
changes and their rationale can then be documented (e.g., via the
‘‘History of Changes’’ link in ClinicalTrials.gov). Date-stamped
copies of protocols can also be uploaded onto researchers’ host
institution study website or research funders’ websites, and linked
to registration.
Pre-specification by this route can thus embrace approaches
that emerge during analysis—this applies to both observational
studies and RCTs [48]. Reasons for protocol changes can be
specified initially and at updating, indicating whether additional
analyses were data-driven or not. Reporting these, in the context
of the original protocol, helps better understand and assess the
results. The REMARK reporting profile encourages broad
analysis strategies to be pre-specified at registration, but recognises
other data-driven analyses may emerge [28]. As a minimum,
journal editors could require protocol availability at the time of the
publication of research results. Ideally, however, accessibility
should align with registration (Figure 1). Regardless of whether
and where the protocol is made publicly available or accessible, it
should be ‘‘date stamped’’ for future reference.
Conclusions and Recommendations
We have argued that the quality of prognosis research could be
substantially improved by the adoption and promotion of
straightforward methods to improve transparency. The range of
ethical and scientific benefits that should accrue from the adoption
of transparency measures outlined in this report extends beyond
just those considered here and Table 2 provides a summary. Our
recommendations (summarised in Table 3) are designed to
encourage prognosis researchers to realise these benefits.
Complete and accurate reporting of all components of a
prognosis study could be achieved by application of existing but
underused published reporting guidelines (recommendation 1). We
propose that extended versions of the existing REMARK
guidelines for tumour marker studies should be developed for
application to all prognosis research.
Data sharing for prognosis research is still uncommon, but there
are good examples of the benefits of accessible and combined
datasets, notably for IPD meta-analyses. We recommend that data
Figure 1. Illustration of the timing of prognosis study registration, protocol publication, data sharing, and reporting.
doi:10.1371/journal.pmed.1001671.g001
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Potential Benefit Registration Protocols Reporting Sharing
Ethical
Respect the investigator-participant covenant to generate new,
publicly accessible biomedical knowledge of potential value to
future patients
XXX X
Facilitate monitoring and accountability in relation to global
standards for ethical research, including informed consent
XXX
Cost-effective use of public money X X X X
Scientific
Improve the quality and reliability of evidence from prognosis
research, (and thereby enhance impact on health and health care)
XXX X
Help accelerate knowledge creation through easier identification
of and access to full study details, including data, in order to
increase opportunities for collaboration including systematic
reviews and meta-analysis
XXX X
Answer research questions only possible through collaboration X
Reduce unnecessary duplication of invested research resources
through awareness of existing studies
XX
Establish intellectual property X
Provide a denominator against which publication bias can be
assessed
XX
Provide means for identification and prevention of biased
under-reporting or over-reporting of research
XX
Involve patients in studies, including enrolment X X
Peer review of protocols to improve study quality and refine
methods
X
Methodological issues sufficiently detailed to, in principle, allow
study replication (details not always allowable in published reports)
X
doi:10.1371/journal.pmed.1001671.t002
Table 3. Recommendations.
Number Recommendation
1 Full study reporting through use of guidelines
N Extended versions of REMARK guidelines to be developed for prognosis research
2 Facilitate and expect data sharing
N Promote standardised case definitions and outcome measures
N Create culture where data sharing is a positive achievement
3 Routine registration of all prognosis studies using existing registers
N Establish minimal dataset (startpoint; list of candidate factors)
N Broad analysis plan included, allowing for updates
N Register before data acquisition in new cohorts and before sampling and analysis in established datasets
4 Protocols for all prognosis studies made public
N Encourage early public accessibility through linkage to registration record or journal publication
N Original protocol and amendments should be available when results submitted for publication
N Align standard elements of protocol with guidelines for publication and core registration dataset
N Date stamp electronic protocols—update with revision
5 Promote systematic development and evaluation of methods and value of transparency
N Objective basis for change and improvement
N Systematic evaluation of adoption of transparency measures and their impact
doi:10.1371/journal.pmed.1001671.t003
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and that standardisation of measures in prognosis studies should
be promoted (recommendation 2).
Registration of RCTs has required changes not only in editorial
policy, legislation, and regulation, but also in research culture, and
further improvements are still needed [53] We consider the lack of
an ideal registration culture in trials is not an argument against
registration of prognosis studies. Registration is a simple low-cost
initiative that we recommend for all prognosis research studies
(recommendation 3). An agreed minimal dataset should be
developed for this purpose.
Study protocols extend the detail available in registers. It seems
reasonable to encourage protocols for all prognosis research
(recommendation 4) since research funders and many large
cohorts require them de facto. We also recommend early
accessibility and public availability of prognosis research protocols.
Journal publication is an important method of making protocols
readily available, and there should be a minimum requirement for
a protocol to be accessible at the time of publication of the results
of the study. However linking accessible time-stamped protocols to
study registration would achieve accessibility for all registered
studies and allow data analysis proposals to be updated during the
evolution of a study whilst retaining the original protocol.
Finally transparency itself requires systematic approaches to
developing methods to achieve improvement (for example,
evidence-based consensus on core content of registration record
for prognosis studies). We conclude also that there must be critical
and systematic evaluation of the success of these methods in
achieving the aims of transparency, namely better quality
prognosis research, more efficient use of available data, and a
research culture that can keep pace with rapidly expanding clinical
and health care data in an era of greater patient involvement and
public accountability (recommendation 5).
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